This result may be in line with previous studies in EAE and MS, which pointed to a role of the NLRP3 inflammasome and its related cytokine, IL-1β, in the effective clinical response to IFN-β in EAE mice and RRMS patients [29, 30]. The gene discussed is IL1B; the disease is relapsing-remitting multiple sclerosis.